{"name":"Taiho Pharmaceutical Co., Ltd.","slug":"taiho-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"taiho.com","description":"","hq":"Tokyo","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"immunology","drugs":[{"name":"Cisplatin (arm B)","genericName":"Cisplatin (arm B)","slug":"cisplatin-arm-b","indication":"Metastatic testicular cancer","status":"phase_3"},{"name":"CPT-11, 5-FU and l-LV","genericName":"CPT-11, 5-FU and l-LV","slug":"cpt-11-5-fu-and-l-lv","indication":"Colorectal cancer","status":"phase_2"},{"name":"Gemcitabine plus TS-1","genericName":"Gemcitabine plus TS-1","slug":"gemcitabine-plus-ts-1","indication":"Pancreatic cancer","status":"phase_3"},{"name":"Jeselhy","genericName":"Pimitespib","slug":"pimitespib","indication":"Gastrointestinal stromal tumor","status":"marketed"},{"name":"S-1 + Cisplatin (arm A)","genericName":"S-1 + Cisplatin (arm A)","slug":"s-1-cisplatin-arm-a","indication":"Gastric cancer","status":"phase_3"},{"name":"S-1 plus CDDP","genericName":"S-1 plus CDDP","slug":"s-1-plus-cddp","indication":"Gastric cancer","status":"phase_3"},{"name":"S-1 plus Cisplatin","genericName":"S-1 plus Cisplatin","slug":"s-1-plus-cisplatin","indication":"Advanced gastric cancer","status":"phase_3"},{"name":"TAS-118 plus Oxaliplatin","genericName":"TAS-118 plus Oxaliplatin","slug":"tas-118-plus-oxaliplatin","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"TS-1 and cisplatin","genericName":"TS-1 and cisplatin","slug":"ts-1-and-cisplatin","indication":"Advanced gastric cancer","status":"phase_3"},{"name":"UFT (uracil, tegafur)","genericName":"UFT (uracil, tegafur)","slug":"uft-uracil-tegafur","indication":"Colorectal cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"AB122","genericName":"AB122","slug":"ab122","indication":"Other","status":"phase_1"},{"name":"ASTX030","genericName":"ASTX030","slug":"astx030","indication":"Other","status":"phase_1"},{"name":"AB154","genericName":"AB154","slug":"ab154","indication":"Other","status":"phase_1"},{"name":"Placebo [Ambulatory Cohort] only","genericName":"Placebo [Ambulatory Cohort] only","slug":"placebo-ambulatory-cohort-only","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"AB122","genericName":"AB122","slug":"ab122","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASTX030","genericName":"ASTX030","slug":"astx030","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cisplatin (arm B)","genericName":"Cisplatin (arm B)","slug":"cisplatin-arm-b","phase":"phase_3","mechanism":"Cisplatin is a platinum-based chemotherapy agent that forms DNA adducts and crosslinks, preventing DNA replication and triggering cancer cell death.","indications":["Metastatic testicular cancer","Metastatic ovarian cancer","Advanced bladder cancer","Head and neck cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"AB154","genericName":"AB154","slug":"ab154","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CPT-11, 5-FU and l-LV","genericName":"CPT-11, 5-FU and l-LV","slug":"cpt-11-5-fu-and-l-lv","phase":"phase_2","mechanism":"Topoisomerase I inhibitor","indications":["Colorectal cancer","Breast cancer"],"catalyst":""},{"name":"Gemcitabine plus TS-1","genericName":"Gemcitabine plus TS-1","slug":"gemcitabine-plus-ts-1","phase":"phase_3","mechanism":"Gemcitabine plus TS-1 is a combination chemotherapy regimen that inhibits DNA synthesis and disrupts nucleotide metabolism to kill rapidly dividing cancer cells.","indications":["Pancreatic cancer","Gastric cancer","Biliary tract cancer"],"catalyst":""},{"name":"Jeselhy","genericName":"Pimitespib","slug":"pimitespib","phase":"marketed","mechanism":"Heat shock protein HSP 90-beta","indications":["Gastrointestinal stromal tumor"],"catalyst":""},{"name":"Placebo [Ambulatory Cohort] only","genericName":"Placebo [Ambulatory Cohort] only","slug":"placebo-ambulatory-cohort-only","phase":"phase_3","mechanism":"Placebo has no active pharmacological mechanism; it serves as a control comparator in clinical trials.","indications":[],"catalyst":""},{"name":"S-1 + Cisplatin (arm A)","genericName":"S-1 + Cisplatin (arm A)","slug":"s-1-cisplatin-arm-a","phase":"phase_3","mechanism":"S-1 is an oral fluoropyrimidine prodrug that inhibits thymidylate synthase and other enzymes in nucleotide synthesis, while cisplatin is a platinum-based alkylating agent that cross-links DNA, together producing synergistic cytotoxic effects against cancer cells.","indications":["Gastric cancer","Gastroesophageal junction cancer","Esophageal cancer"],"catalyst":""},{"name":"S-1 plus CDDP","genericName":"S-1 plus CDDP","slug":"s-1-plus-cddp","phase":"phase_3","mechanism":"S-1 plus CDDP is a combination chemotherapy regimen that inhibits thymidylate synthase and causes DNA cross-linking to suppress cancer cell proliferation.","indications":["Gastric cancer","Gastroesophageal junction cancer","Esophageal cancer"],"catalyst":""},{"name":"S-1 plus Cisplatin","genericName":"S-1 plus Cisplatin","slug":"s-1-plus-cisplatin","phase":"phase_3","mechanism":"S-1 is a fluoropyrimidine derivative that inhibits thymidylate synthase, while cisplatin is a platinum-based alkylating agent that cross-links DNA, thereby inhibiting DNA replication and transcription.","indications":["Advanced gastric cancer","Pancreatic cancer"],"catalyst":""},{"name":"TAS-118 plus Oxaliplatin","genericName":"TAS-118 plus Oxaliplatin","slug":"tas-118-plus-oxaliplatin","phase":"phase_3","mechanism":"TAS-118 is a thymidylate synthase inhibitor, and when combined with oxaliplatin, it targets rapidly dividing cancer cells.","indications":["Metastatic colorectal cancer"],"catalyst":""},{"name":"TS-1 and cisplatin","genericName":"TS-1 and cisplatin","slug":"ts-1-and-cisplatin","phase":"phase_3","mechanism":"TS-1 is a prodrug that is converted into 5-fluorouracil (5-FU) in the body, which is then incorporated into DNA and RNA, interfering with DNA replication and transcription, and cisplatin is a platinum-based chemotherapy drug that works by cross-linking DNA, thereby inhibiting DNA replication and transcription.","indications":["Advanced gastric cancer","Pancreatic cancer"],"catalyst":""},{"name":"UFT (uracil, tegafur)","genericName":"UFT (uracil, tegafur)","slug":"uft-uracil-tegafur","phase":"phase_3","mechanism":"UFT is a combination of uracil and tegafur that inhibits thymidylate synthase to block DNA synthesis and induce cancer cell death.","indications":["Colorectal cancer","Gastric cancer","Breast cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxPNEpiODQ0MkZNRlo0UFVBcTQ2a0dPTllwbjZtS0tuekRCNkMtMjdWX1haNkFUSnBfTzBrMlpHbGRXU2w0cUsxT3h1ck5hZGM4WjZnWTBvTGlNdmZFSjBfQ216bl94V19wY09RRjJGYWZ4VGtSTFIzWkxuSC16X0plSXhjUk1BUHVXX0F0R3FZVERNd3otUWlRSERxNW5GYmRiOURoNElJR2NETUJmeDNYUTBvOXBfUUtOT3lEdndac3hlem0wTkZjcEh2QTQ5dzBSbEI3dElFQ1pBOHFvem5jU2Mxcw?oc=5","date":"2026-02-19","type":"deal","source":"PRWeb","summary":"Demeetra Announces Renewal of Research License for piggyBac® Technology with Taiho Pharmaceutical Co., Ltd. - PRWeb","headline":"Demeetra Announces Renewal of Research License for piggyBac® Technology with Taiho Pharmaceutical Co., Ltd.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQUlJUcGstWVVQQ3Q4eHVjSGpGZWh6UmZ6MmYwV21JOWhrYjRWVUNteEpOckU0UHkwaVdfendycWFEZ1hkREdQLUVIdjJWSnplNVQ4V19DUG9pNE8yMTFTc3VueHVXMmliWWpYNGN3eHF4OWg2ZFpiY005SUc4QWRvaUhHaDV0a1VKOXBUZjBoQXRtTjdza2pOS3JpWE5LZ0hLc0pRamdCT2swdWU1cWpJ?oc=5","date":"2026-01-21","type":"pipeline","source":"BioSpace","summary":"Peter Melnyk Joins Taiho Oncology as President & Chief Operating Officer - BioSpace","headline":"Peter Melnyk Joins Taiho Oncology as President & Chief Operating Officer","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-20","type":"pipeline","source":"prnewswire.com","summary":"Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanc","headline":"Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxNaEhEb1Q0X1p1c2pXUXpoVXBWRW40YnRKOTRZbGlneVZyN1ZwUW5sZWNBaUh3TEtsUUZOdkpYV2hGTnpvYW1YWkJkUy1YNm1yRGdPLTNnRHFPTy1HTF9Od01ybGlxMGp1RG5WMUdXeUc1aGl5T3REcjJncW1RZERGWmJVbHZxemNNdzE5Zms4QnRVRk44ckJJT3loUXJ6VV9la3Ftc1lPYW1rUHF6aXVZbWRuZnU1NXZYNW12ZlZqalpLbjdnT1hyTDFERXdXN1g1RFM5bmQ1NGNIZkdFa1RkT0lVTFFLeHQ2QzVqbWRhM3NWUUhEVVZZYWEzT1NRVUVSTm1vbmhwTXktTTNoMTlnb1c5S0dSNHc5LVV1T3h6VURVZw?oc=5","date":"2025-07-22","type":"pipeline","source":"prnewswire.com","summary":"Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer - prnewswire.com","headline":"Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Confe","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-09","type":"regulatory","source":"prnewswire.com","summary":"Taiho Oncology and Taiho Pharmaceutical Announce U.S. FDA Acceptance of Supplemental New Drug Application for INQOVI® in Combination with Venetoclax to Treat Patients with Acute Myeloid Leukemia - prn","headline":"Taiho Oncology and Taiho Pharmaceutical Announce U.S. FDA Acceptance of Supplemental New Drug Application for INQOVI® in","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-25","type":"patent","source":"medicaldialogues.in","summary":"Delhi HC Quashes IPO's Patent Rejection of Taiho Pharma's Cancer Drug, Orders Re-evaluation - medicaldialogues.in","headline":"Delhi HC Quashes IPO's Patent Rejection of Taiho Pharma's Cancer Drug, Orders Re-evaluation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxOQ1BHeTNMbkpxcmpndGNuTDFuNTIwYWR6QWpjbFVNVmIzb2xWODBnRVk0Z3lQWG1WMnEyN3BYYTJ2RnhFNV9oWWNaX0RoWHE2YUFNZjBPQmNQMDNacm16c1Mxbnc1VTFkeWxEWWZfWTRndURXMVgyOHdKbDVWR2xzWU1sOExRbGJGRG1yNXhGYkVkU3BhQU9YRXd0cDJaV1JJNUdCbV9wVTg4a3ozYlJ0WVdaNzNqZUJfeEo1cHh4RExueVY1YlRCMklheUI5Ni1EZUZtcUN5UFllbExmYVJBclMxMW9kYzhnYm5XVDlEUF9ZenM?oc=5","date":"2025-03-17","type":"deal","source":"GlobeNewswire","summary":"Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech - GlobeNewswire","headline":"Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQUjVsRUJyMUJRVXIyaFVodjNQanBhTERsd3pZNmRtUGhTS24xYnJsQlhMMHMzckFLaVpDSUxyaXd3TXBscDFGV1Noanp1UGhWakFRSGdLR1RJcU1obVFTVVRvMDFKSlNGcjNQZUFQeUhEQ1Y1UFBHRkJycXhKMjY1dzFidVRRVEs1MjA3bVhYUzBUZkIwbHJNbmFWeXdsbzdKdWxZ?oc=5","date":"2025-03-17","type":"deal","source":"Pharmaceutical Technology","summary":"Taiho outlays $1.14bn to acquire ADC specialist Araris - Pharmaceutical Technology","headline":"Taiho outlays $1.14bn to acquire ADC specialist Araris","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOZW9QT003T0R6ZVlON25IMW5ndC01blB2b01hQk9GcUpZLXJoMFhTYU5DekhEVjVOb0NUR0tvTXh5bUU4TVY5SG9VUENTeFdmS2xZREdETU80SnhvMkJKS05HSnZydnhNMklucHg1c29RS3JJMXFEb3pwQU9OYUlFaWNXS25VZk1OM2NaeTFBb3hiNFo2VnJUdzhiLWJtTFdRbkNpdUkxelVQX19BVjl1NDduYWlMa0RCTXhPcHZ3?oc=5","date":"2025-02-11","type":"pipeline","source":"Stanford Graduate School of Business","summary":"Product Manager Leads Global Team Developing New Cancer Drug - Stanford Graduate School of Business","headline":"Product Manager Leads Global Team Developing New Cancer Drug","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-28","type":"trial","source":"prnewswire.com","summary":"Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Inser","headline":"Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipal","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPanlMVEd2N1VVbExrTS02X3h0Z09VSUpvbFozZTJFbGpONVplbS0xRnNoXzZDU1ZlZ1dSZW1CMllpZTlnSEJJeVROU2VEamsyTzE4YWFQUy1wQ2E2b0dLM21sNkVQaU9rMGMxcWRGOXBVRnJYcFI3MGl1cTdreFRlWm5hN0pQcm1VcXFlbXhrQkgtc0VpM2dWQ0tnZmdheU51WU1QUGU4NXhlMGYyYWdCMUc2eWRHbnl4ejM1bGhob0ZKT29pQlBkRlVUSVVvQlpfeWdqbFBGem4yUFBkdk51V0xoZThzaG1wZFlR?oc=5","date":"2023-11-17","type":"trial","source":"prnewswire.com","summary":"Taiho Oncology and Astex Pharmaceuticals Announce Data Presentations at the 65th ASH Annual Meeting - prnewswire.com","headline":"Taiho Oncology and Astex Pharmaceuticals Announce Data Presentations at the 65th ASH Annual Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wJBVV95cUxNS3lGdUN6Sk13NWtrVFF4MG9taUJhMVBCdnhxTV9wd3pEb2Jvckdma1pxNnc1U2F3UmFtdVVtZkhPVzAybnp0UmFyRmNBX3NiV3g3Q24tTFVwaV9XdTNOUUxwU1pVS2JvOWJ0SmhZZHJiU21EUUltZGVHM3ZBQVlEZ3psLUVVWldVMXlRc0J6MjJFQnBGbTZybFlRbEFiOWJZZVlibkNKSHdRV1k1allmWVlKV3ZTbWZsTDFZcGhmaFZlV1RVeFZVUDdqQk55Y0xOb1c1WHZ6anUwcGJrMWtXbFFtTzl4M0FKTGJ1ZGxmOEwzOE1PZkRkamhlZVhGYlRqck1IY1g4T3QxX0FZNFItLWduOTB5NHNITnJsQWktNUlORHVaeU50R0xlcldDamZweVhzb2dLV3UtRGxQQ3ZsSjVWNEVkV0tzVUJ1Y0U4MjRIWFhMcEZUclU5WW04OUk?oc=5","date":"2022-05-12","type":"pipeline","source":"GlobeNewswire","summary":"Cullinan Oncology and Taiho Pharmaceutical Announce - GlobeNewswire","headline":"Cullinan Oncology and Taiho Pharmaceutical Announce","sentiment":"neutral"}],"patents":[],"drugCount":14,"phaseCounts":{"phase_1":3,"phase_3":9,"phase_2":1,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}